New combo aims to tame autoimmune anemia without Long-Term steroids
NCT ID NCT07518277
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding sirolimus to standard steroid treatment helps people with newly diagnosed mild autoimmune hemolytic anemia (AIHA) achieve lasting remission. About 216 adults will be randomly assigned to get either steroids alone or steroids plus sirolimus for 6 months, then followed for 2 years. The main goal is to see if more people in the combo group can stop steroids and stay in remission at 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sirolimus combined with glucocorticoids (steroids)
- What this could lead to
- If it works, this could offer a way to treat AIHA with fewer steroids and a higher chance of staying in remission without ongoing medication.
- What could go wrong
- This is an early-stage trial with no phase assigned, so results are uncertain. Sirolimus can cause side effects like infections or metabolic issues, and the benefit over steroids alone may be small.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking union medical college hospital
Beijing, Shuangfuyuan, NO I., 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tame autoimmune anemia?
- Can a new drug calm the immune System's attack on blood cells?
- Engineered immune cells take aim at stubborn blood disorder
- New pill could help patients with rare blood disorder
- Experimental mRNA CAR-T therapy targets autoimmune diseases in first human trial
- New drug IASO-782 aims to tame immune attacks on blood cells